Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.95 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.85 |
| ▸ | LDHB | P07195 | 4/20 | 0.42 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11906224 | 1.00 | KDM1A (0.95) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL31066574 | 0.97 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL18902532 | 0.97 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL49226 | 0.97 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL21476977 | 0.97 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL25641510 | 0.97 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL21474097 | 0.97 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL29394303 | 0.97 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL14845813 | 0.97 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL21474060 | 0.96 | KDM1A (0.96) | KDM1ARCOR1LDHBTERF2IPESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154605-A | Application of dehydrorhynchophylline in preparation of drug for reducing toxicity of polymyxin | 中国农业大学 | 2025-06-17 | — | — | CN | claimed |
| CN-119424603-A | Inhalation preparation of compound polymyxin and application of inhalation preparation in preparation of medicines for treating lung infection | 凯飞诺泰州生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118787631-A | Application of alpha-naphthacene flavone in preparation of medicines for reducing polymyxin cytotoxicity and/or organ toxicity, pharmaceutical composition and application | 中国农业大学 | 2024-10-18 | — | — | CN | claimed |
| CN-118688340-A | Method for detecting polymyxin E1 and E2 in blood plasma by LC-MS/MS method | 中国人民解放军联勤保障部队第九六〇医院 | 2024-09-24 | — | — | CN | claimed |
| CN-118340768-A | Application of ellagic acid in preparation of medicines for reducing polymyxin cytotoxicity and/or neurotoxicity and nephrotoxicity, pharmaceutical composition and application | 中国农业大学 | 2024-07-16 | — | — | CN | claimed |
| CN-110974937-B | Polymyxin E liposome and preparation method and application thereof | 上海景峰制药有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-116617436-B | Antibacterial dressing and preparation method thereof | 南京医科大学第二附属医院 | 2023-12-19 | — | — | CN | claimed |
| CN-117074475-A | Method for detecting metal sulfate content in extraction process of polymyxin E sulfate | 河北圣雪大成唐山制药有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| CN-115369056-B | Selective medium for separating lactobacillus and application of selective medium in intestinal lactobacillus separation | 山西农业大学 | 2023-10-20 | — | — | CN | claimed |
| CN-116617436-A | Antibacterial dressing and preparation method thereof | 南京医科大学第二附属医院 | 2023-08-22 | — | — | CN | claimed |
| CN-115634280-A | Antibacterial pharmaceutical composition and preparation method and application thereof | 首都医科大学 | 2023-01-24 | — | — | CN | claimed |
| CN-115369056-A | Selective medium for separating lactic acid bacteria and application of selective medium in intestinal lactic acid bacteria separation | 山西农业大学 | 2022-11-22 | — | — | CN | claimed |
| CN-110845579-B | Polymyxin E component and photochemical product thereof and liquid chromatography-mass spectrometry analysis method | 上海市食品药品检验研究院 | 2022-04-19 | — | — | CN | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12569508-B2 | Antimicrobial compositions and methods of use | UNIV SOUTH AUSTRALIA (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12569534-B2 | Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria | ACADEMIA SINICA (TW) | 2026-03-10 | — | — | US | disclosed |
| WO-2015111013-A2 | COLISTIN SYNTHETASES AND CORRESPONDING GENE CLUSTER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-07-30 | — | — | WO | disclosed |
| EP-2734203-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING A RESPIRATORY DISEASE | Eberhard-Karls-Universität Tübingen Universitätsklinikum (DE) | 2014-05-28 | — | — | EP | disclosed |
| CN-103396475-A | Pure-solid-phase synthesis method of polypeptide antibiotic Colistin | SHENZHEN HYBIO PHARMACEUTICAL | 2013-11-20 | — | — | CN | disclosed |
| WO-2013011019-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING A RESPIRATORY DISEASE | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM (DE) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569534-B2 | Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria | PHOSPHO1, CUTA, PCTP | KDM1A 4178/4885RCOR1 4303/4885LDHB 935/4885 |
| US-12569508-B2 | Antimicrobial compositions and methods of use | PCTP, PYCARD, PLIN3 | KDM1A 4181/4885RCOR1 4854/4885LDHB 2340/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KDM1A 2620/4885RCOR1 2321/4885LDHB 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.